WEED vs. CRON, GUD, ACB, TLRY, BHC, DNTL, SIA, WELL, EXE, and FRX
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Cronos Group (CRON), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Tilray Brands (TLRY), Bausch Health Companies (BHC), dentalcorp (DNTL), Sienna Senior Living (SIA), WELL Health Technologies (WELL), Extendicare (EXE), and Fennec Pharmaceuticals (FRX). These companies are all part of the "medical" sector.
Cronos Group (TSE:CRON) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations.
Cronos Group has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Cronos Group has higher earnings, but lower revenue than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
In the previous week, Canopy Growth had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Canopy Growth and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.50 beat Canopy Growth's score of 0.35 indicating that Canopy Growth is being referred to more favorably in the news media.
13.1% of Cronos Group shares are held by institutional investors. Comparatively, 4.9% of Canopy Growth shares are held by institutional investors. 46.7% of Cronos Group shares are held by company insiders. Comparatively, 19.0% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Canopy Growth received 571 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 51.11% of users gave Cronos Group an outperform vote.
Canopy Growth has a net margin of 0.00% compared to Canopy Growth's net margin of -84.78%. Canopy Growth's return on equity of -6.30% beat Cronos Group's return on equity.
Cronos Group currently has a consensus price target of C$2.77, indicating a potential downside of 19.24%. Canopy Growth has a consensus price target of C$3.20, indicating a potential downside of 73.55%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Canopy Growth.
Summary
Cronos Group beats Canopy Growth on 9 of the 17 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for WEED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
